Tumor treating fields for high-grade gliomas

Chengke Luo, M.D.; Shengchao Xu, M.D.; Gan Dai, M.D.; Zhiqiang Xiao, M.D.; Ling Chen, M.D.; Zhixiong Liu, M.D.

Biomedicine & Pharmacotherapy (Jul 2020)

Tumor treating fields for high-grade gliomas

Chengke Luo, M.D.,
Shengchao Xu, M.D.,
Gan Dai, M.D.,
Zhiqiang Xiao, M.D.,
Ling Chen, M.D.,
Zhixiong Liu, M.D.

Affiliations

Chengke Luo, M.D.: Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha 410008, Hunan, China
Shengchao Xu, M.D.: Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha 410008, Hunan, China
Gan Dai, M.D.: Department of Microbiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China
Zhiqiang Xiao, M.D.: Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital of Central South University, Changsha, Hunan, China; Corresponding author at: Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital of Central South University, No.87, Xiangya Road, Changsha, Hunan 410008, China.
Ling Chen, M.D.: Department of Neurosurgery, Chinese People's Liberation Army of China (PLA) General Hospital, Medical School of Chinese PLA, Institute of Neurosurgery of Chinese PLA, Beijing, 100853, China; Corresponding author at: Department of Neurosurgery, Chinese People's Liberation Army of China (PLA) General Hospital, Medical School of Chinese PLA, Institute of Neurosurgery of Chinese PLA, Beijing, 100853, China.
Zhixiong Liu, M.D.: Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha 410008, Hunan, China; Corresponding author at: Department of Neurosurgery, Xiangya Hospital, Central South University, No.87, Xiangya Road, Changsha, Hunan 410008, China.

Journal volume & issue: Vol. 127
p. 110193

Abstract

Read online

High-grade gliomas (HGG) are the most common malignant intracranial tumors with poor prognosis. Current treatments have not yielded optimal remission rates; there are no standard treatments for recurrent and drug-resistant gliomas. Tumor treating fields, which was recently approved by the Food and Drug Administration (FDA), could significantly improve progression free survival and the overall survival of glioma patients. In this review, we elaborate on the mechanism of tumor treating fields in tumor cells and detail various preclinical and clinical studies on gliomas. Tumor treating fields could be a promising option for patients with malignant tumors for which there are no standard treatment plans. Moreover, we identify several potential problems for the practical application of tumor treating fields and predict future directions for further studies. Tumor treating fields may be a potential therapy with high efficacy, fewer adverse effects, and high cost-effectiveness.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords